Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...